Active Biotech AB (publ) (STO:ACTI)

Active Biotech AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	12.16	12.36	13.17	13.94	15.06	15.25
Research & Development	22.84	25.24	26.67	32.54	42.82	34.54
Operating Expenses	35	37.6	39.84	46.48	57.89	49.78
Operating Income	-35	-37.6	-39.84	-46.48	-57.89	-49.78
Interest Expense	-0.11	-0.11	-0.18	-0.24	-0.21	-0.03
Interest & Investment Income	0.43	0.43	0.65	0.29	0.05	-
Currency Exchange Gain (Loss)	-0.04	-0.04	-0.03	0.07	-0.01	0.02
EBT Excluding Unusual Items	-34.72	-37.32	-39.4	-46.37	-58.05	-49.79
Gain (Loss) on Sale of Investments	-	-	-	0.57	-0.32	-0.03
Pretax Income	-34.72	-37.32	-39.4	-45.8	-58.37	-49.83
Net Income	-34.72	-37.32	-39.4	-45.8	-58.37	-49.83
Net Income to Common	-34.72	-37.32	-39.4	-45.8	-58.37	-49.83
Shares Outstanding (Basic)	1,699	1,347	420	272	234	214
Shares Outstanding (Diluted)	1,699	1,347	420	272	234	214
Shares Change (YoY)	166.46%	220.46%	54.84%	16.21%	9.23%	26.87%
EPS (Basic)	-0.02	-0.03	-0.09	-0.17	-0.25	-0.23
EPS (Diluted)	-0.02	-0.03	-0.09	-0.17	-0.25	-0.23
EBITDA	-	-36	-38.24	-44.78	-57.89	-48.48
D&A For EBITDA	-	1.6	1.6	1.7	0	1.3
EBIT	-35	-37.6	-39.84	-46.48	-57.89	-49.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.